Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in patients from a major military treatment facility.
about
"Stormy waters ahead": global emergence of carbapenemasesAcinetobacter baumannii isolates from pets and horses in Switzerland: molecular characterization and clinical dataCarbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination.Diversity and clinical impact of Acinetobacter baumannii colonization and infection at a military medical center.Fulminant endocarditis and disseminated infection caused by carbapenem-resistant Acinetobacter baumannii in a renal-pancreas transplant recipient.Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii.Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosisAcinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.Antimicrobial resistance determinants in Acinetobacter baumannii isolates taken from military treatment facilities.Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III.Status report on carbapenemases: challenges and prospects.The enhanced permeability retention effect: a new paradigm for drug targeting in infection.Emergence of carbapenem non-susceptible multidrug resistant Acinetobacter baumannii strains of clonal complexes 103(B) and 92(B) harboring OXA-type carbapenemases and metallo-β-lactamases in Southern India.The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection.Resistant Gram-Negative Bacteria and Diagnostic Point-of-Care Options for the Field Setting during Military Operations.
P2860
Q21131125-720680BC-C9B0-4E20-A299-61328A3927C2Q33953265-AB9A0BA6-2998-4E9A-9FD5-3A7685D34619Q33997664-A47FD042-E5CE-4133-90E5-2ACA80157202Q34487712-C8418D16-BFED-4855-85AF-9654D2ECE629Q35235590-0D786234-5A37-482A-9003-3821F67E21E6Q36405521-A7AA26B7-E339-4F92-BB10-AF49C0516FE5Q36457770-35AF6EB8-F700-4805-947F-E0B3EF0380BCQ36569183-810CFB22-4C77-4244-A7CD-6CB217F0DAC0Q37544784-C30EC842-F48B-4E32-A875-9D650719135DQ37581847-9DA005EE-AB04-469F-B060-B1794FEDF34EQ37879199-C3FC0D27-9D6D-4A5C-B349-649B9A976FDDQ38051263-8B5F5E64-2B3A-430E-A8BE-DA797657BF64Q41333427-6F039DEF-4FF3-42F9-A9F6-E66C19928230Q54215616-A7901721-2061-47CC-BE6D-A9F8A4435259Q55662425-688BD974-696C-495D-A0B7-C880D58886D9
P2860
Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in patients from a major military treatment facility.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Antibiotic resistance determin ...... r military treatment facility.
@ast
Antibiotic resistance determin ...... r military treatment facility.
@en
type
label
Antibiotic resistance determin ...... r military treatment facility.
@ast
Antibiotic resistance determin ...... r military treatment facility.
@en
prefLabel
Antibiotic resistance determin ...... r military treatment facility.
@ast
Antibiotic resistance determin ...... r military treatment facility.
@en
P2093
P2860
P50
P1476
Antibiotic resistance determin ...... r military treatment facility.
@en
P2093
David Aron
Edward A Hulten
Federico Perez
Joel Fishbain
Katherine Thweatt
Kristine M Hujer
P2860
P356
10.1016/J.AJIC.2009.05.007
P577
2009-09-24T00:00:00Z